Back to Search
Start Over
Metabolic syndrome and breast cancer survivors: a follow-up analysis after completion of chemotherapy
- Source :
- Diabetologymetabolic syndrome. 14(1)
- Publication Year :
- 2021
-
Abstract
- Background We previously reported that (neo)adjuvant chemotherapy adversely altered metabolic syndrome (MetS) components, body composition, and related biomarkers after a 12 to 18-week chemotherapy treatment course in women. Here, we sought to determine whether these measures worsened within 4–5 years post-chemotherapy among the same sample of early stage breast cancer survivors. Methods Twenty-eight breast cancer survivors were reassessed within 4–5 years post-chemotherapy. Participants were tested for MetS, lipid profile (total cholesterol; TC, low-density lipoprotein cholesterol; LDL-C), glucose metabolism (insulin, homeostatic model- insulin resistance; HOMA-IR, glycosylated hemoglobin; HbA1c), inflammation (C-reactive protein; CRP) and body composition (body weight; BW, percent body fat; BF, fat mass; FM) during follow-up physical exams. A comparison of measurements between post-chemotherapy and follow-up periods was performed using repeated measures analysis of covariance. Results Most study patients were Caucasian (44%) or Hispanic (30%) with a mean age of 48.2 years. Average time from completion of chemotherapy was 4.75 years. At follow-up, MetS components significantly increased (p Conclusion MetS components, body composition, and biomarkers continued to worsen within 4–5 years post-chemotherapy in breast cancer survivors. Energy balance interventions should target breast cancer patients to reduce the exacerbation of MetS.
- Subjects :
- Endocrinology, Diabetes and Metabolism
Internal Medicine
Subjects
Details
- ISSN :
- 17585996
- Volume :
- 14
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Diabetologymetabolic syndrome
- Accession number :
- edsair.doi.dedup.....545336a3d9b27d73b6b4649e12fe63b1